Takeda signs option deal for MacroGenics bi-specific antibody
This article was originally published in Scrip
Takeda Pharmaceutical will pay MacroGenics $15m up front for an option to license the early-stage bi-specific antibody MGD010 for autoimmune diseases in an agreement worth up to $501.5m plus royalties.
You may also be interested in...
MacroGenics has regained global rights to one of its DART compounds from Takeda, following a reprioritization of therapeutic areas by the Japanese firm that may open up new partnering opportunities in autoimmune disorders.
Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.